AstraZeneca Halts Phase IIb Trial of Potential Sepsis Drug

Drug Industry Daily
A A
AstraZeneca and its partner BTG are halting development of a severe sepsis and septic shock drug candidate because it did not show any improvement over placebo in a Phase IIb clinical trial.

To View This Article:

Login

Subscribe To Drug Industry Daily